D 2006

Molecular characterization of primary colorectal cancers with progressive metastatic phenotype by oligonucleotide microarrays

SLABÝ, Ondřej, Ingrid GARAJOVÁ, Marek SVOBODA, Miroslav SVOBODA, Rostislav VYZULA et. al.

Základní údaje

Originální název

Molecular characterization of primary colorectal cancers with progressive metastatic phenotype by oligonucleotide microarrays

Název česky

Molekulární charakterizace progredujícího metastatického kolorektalního karcinomu pomocí oligonukleotidových makročipů

Autoři

SLABÝ, Ondřej (203 Česká republika), Ingrid GARAJOVÁ (703 Slovensko), Marek SVOBODA (203 Česká republika), Miroslav SVOBODA (203 Česká republika) a Rostislav VYZULA (203 Česká republika, garant)

Vydání

Piešťany, sborník XX. BIOCHEMICKÝ ZJAZD, s. 213-213, 2006

Nakladatel

Slovenská společnost pro biochémiu a molekulárnu biologii, člen IUMBM a FEBS

Další údaje

Jazyk

angličtina

Typ výsledku

Stať ve sborníku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Kód RIV

RIV/00216224:14110/06:00017176

Organizační jednotka

Lékařská fakulta

ISBN

80-969532-6-5

Klíčová slova anglicky

colorectal cancer; DNA microarray technology; gene expression; pathogenesis; prognosis; prediction

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 13. 10. 2007 23:25, prof. MUDr. Marek Svoboda, Ph.D.

Anotace

V originále

PURPOSE: Colorectal cancer (CRC) is one of the most common malignancies. Unfortunately a significant proportion of surgically cured patiens in the early stage of the disease develop progression and die from the disease. This study aimed to find individual up/down-regulated genes associated with progression and metastatic potential of colorectal cancers using low-density oligonucleotide microarrays. Molecular characterization of patients at high risk of cancer progression may assist to oncologists in treatment decision by selecting those patients who will need adjuvant chemotherapy. PATIENTS AND METHODS: Patients who underwent surgical resection were divided into different prognostic groups by disease-free survival (DFS>36 month – good prognosis; DFS<36 month – bad prognosis). Total RNA was extracted from each frozen tumor specimen and gene expression profiles were obtained using a human oligonucleotide microrray (SuperArray) spotted with 128 genes known to be involved in metastasis. Genes with expression levels showing at least a 2-fold difference were identified as differentially expressed. RESULTS: Characteristic gene expression profiles were obtained from tumor specimens of prognostically different patients with CRC. Expression analysis identified 21 differentially expressed genes (19 up-regulated, 2 down-regulated) in primary tumors of patients who had progressive disease (DFS<36). The functional categories of up-regulated genes belonged to cell cycle (MYC, HRAS, TP53), adhesion molecules (cadherins CDH8, CDH11, CDH19; molecule CD44; catenins CTNNA1, CTNNB1; chemokine CXCR4), matrix metalloproteinases (MMP7, MMP9, MMP10, MMP11, MMP13) and prometastatic factors such as growth factor IGF1, metastasis associated protein MTA1, transcription factor ETV4 (e.g. COX-2 and MMP-7 promoters activation) and scaffolding protein CAV1. The lower expression levels showed genes encoding negative cell proliferation regulator NME1 and plasminogen activator PLAUR. All of these expression differences are consistent with previous reports and molecular and cellular aspects of cancer progression and metastasis. CONCLUSIONS: Our preliminary data suggest that oligonucleotide microarray technology should contribute to a better understanding of the progression of colorectal cancers, and facilitate prediction of their metastatic potential. Analyzing of gene expression data from larger group of CRC patients will enable us to identify distinct prognostic subsets of patients based on molecular characteristics in the near future. This work was supported by IGA MZ ČR NR/9076 - 4

Česky

Publikace pouze v anglickém jazyce.

Návaznosti

NR9076, projekt VaV
Název: Genomické profilování v predikci odpovědi na chemoradioterapii u pacientů s lokálně pokročilým karcinomem konečníku